Skip to main content
logo
NextCell Pharma AB (STO:NXTCL)
Sweden flag Sweden · Delayed Price · Currency is SEK
1.010
-0.002 (-0.20%)
Jul 24, 2026, 4:58 PM CET

NextCell Pharma AB Financials Overview

Millions SEK. Fiscal year is Jan - Dec.

Revenue & Profits
Chart
Fiscal YearTTMFY 2025FY 2025FY 2024FY 2024FY 2023
Period EndingMar '26 Dec '25 Aug '25 Dec '24 Aug '24 Aug '23
Revenue
10.6113.9611.0611.2811.2813.96
Revenue Growth
0.59%26.17%-1.90%0%-19.18%124.03%
Gross Profit
2.892.191.67-3.94-3.942.96
Operating Income
-40.14-51.82-35.89-43.17-43.17-41
Net Income
-39.62-50.93-35.14-41.96-41.96-39.81
Earnings Per Share
-0.37-0.60-0.46-1.06-1.03-1.16
EPS Growth
------

Revenue by Segment
Chart
Fiscal YearFY 2025
Period EndingAug '25
Stem Cell Banking
10.53
Other
0.4
Total
10.94

Cash & Debt
Chart
Fiscal YearCurrentFY 2025FY 2025FY 2024FY 2024FY 2023
Period EndingMar '26 Dec '25 Aug '25 Dec '24 Aug '24 Aug '23
Net Cash (Debt)
32.3326.0338.7232.746.7950.03
Net Cash Growth
-31.09%-32.77%18.43%-30.12%-6.47%-48.49%
Cash & Investments
32.3326.0338.7232.746.7950.03
Net Cash Per Share
0.300.310.510.801.151.46

Cash Flow & CapEx
Chart
Fiscal YearTTMFY 2025FY 2025FY 2024FY 2024FY 2023
Period EndingMar '26 Dec '25 Aug '25 Dec '24 Aug '24 Aug '23
Operating Cash Flow
-38.6-50.9-38.86-39.51-37.78-43.83
Capital Expenditures
-3.22-4.97-0.42-0.08-0.08-4.1
Free Cash Flow
-41.83-55.87-39.28-39.6-37.86-47.92
Free Cash Flow Growth
------

Margins
Chart
Fiscal YearTTMFY 2025FY 2025FY 2024FY 2024FY 2023
Period EndingMar '26 Dec '25 Aug '25 Dec '24 Aug '24 Aug '23
Gross Margin
27.19%15.70%15.07%-34.97%-34.97%21.19%
Operating Margin
-378.20%-371.21%-324.35%-382.79%-382.79%-293.81%
Pretax Margin
-373.34%-364.85%-317.62%-372.04%-372.04%-285.28%
Profit Margin
-373.34%-364.85%-317.62%-372.04%-372.04%-285.28%
FCF Margin
-394.08%-400.18%-355.03%-351.10%-335.70%-343.41%

Valuation
Chart
Fiscal YearCurrentFY 2025FY 2025FY 2024FY 2024FY 2023
Period EndingJul '26 Dec '25 Aug '25 Dec '24 Aug '24 Aug '23
PS Ratio
13.815.8311.7818.418.238.87